WO2010117274A1 - Glucides permettant l'amélioration de la production d'un acide gras à chaîne courte c5 et/ou c6 - Google Patents

Glucides permettant l'amélioration de la production d'un acide gras à chaîne courte c5 et/ou c6 Download PDF

Info

Publication number
WO2010117274A1
WO2010117274A1 PCT/NL2010/050187 NL2010050187W WO2010117274A1 WO 2010117274 A1 WO2010117274 A1 WO 2010117274A1 NL 2010050187 W NL2010050187 W NL 2010050187W WO 2010117274 A1 WO2010117274 A1 WO 2010117274A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbohydrate
scfa
composition
subject
detectable
Prior art date
Application number
PCT/NL2010/050187
Other languages
English (en)
Inventor
Konraad Venema
Albert Arjaan De Graaf
Jan Sikkema
Original Assignee
Stichting Top Institute Food And Nutrition
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Top Institute Food And Nutrition filed Critical Stichting Top Institute Food And Nutrition
Publication of WO2010117274A1 publication Critical patent/WO2010117274A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • a carbohydrate may be a non-digestible, non-digested or a digestible carbohydrate.
  • a carbohydrate is preferably an oligosaccharide or a polysaccharide.
  • An oligosaccharide is defined herein as a saccharide polymer with a small number (usually 3 to 10) of components sugars, also known as simple sugars.
  • a polysaccharide is a relatively more complex carbohydrate than an oligosaccharide.
  • Polysaccharides are polymers made up of many monosaccharides joined together by glycosidic bonds.
  • the second time period as defined herein is in principle not dependent on the administration mode since it reflects the time needed by the bacteria from the intestine to ferment a carbohydrate.
  • a carbohydrate is attractive to be used as a medicament for preventing, delaying and/or treating a disorder of the gastrointestinal tract since such said carbohydrate is preferably able to induce a detectable increase of a C5 and/or a C6 SCFA. More preferably, said increase is detectable at least 10 hours after the oral administration of said carbohydrate.
  • said carbohydrate is such that wherein at least 50% of the ingested carbohydrate is fermented in at least 4 hours by the bacteria present in the lumen of the treated subject.
  • TER may be assessed on a gastrointestinal cell from a subject or from a gastrointestinal control cell derived from a cell line.
  • a preferred cell line is Caco2 as used in example 3.
  • a detectable TER increase may be detected at least approximately 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,1 6, 17, 18, 19, 20, 21, 22, 23, or 24 hours after the detection of the presence of a C5 and/or C6 SCFA in a subject or in a cell. It is also encompassed by the present invention, that the induction is detectable after a longer time period than 24 hours.
  • the type of carbohydrate administered may influence the time period at which an induction of a C5 and/or C6 SCFA is detectable and therefore the time period at which a detectable increase of TER is detectable.
  • a TER may be assessed as in example 3 by directly adding a C5 and/or a C6 SCFA to a cell.
  • a preferred bacterium belongs to a genus selected from the group consisting of Lactobacillus, Lactococcus, Leuconostoc, Carnobacterium, Streptococcus, Bifidobacterium, Bacteroides, Eubacterium, Clostridium, Fusobacterium,
  • the food product is a beverage, more specifically a fruit drink, or combination of fruit and dairy drink, it preferably comprises at least 10% by weight of the composition of a fruit component, wherein the fruit component is selected from fruit juice, fruit concentrate, fruit juice concentrate, fruit puree, fruit pulp, comminuted fruit, fruit puree concentrate, and combinations thereof.
  • fruit components are orange juice, apple juice, grape juice, peach pulp, banana pulp, apricot pulp, concentrated orange juice, mango pulp, concentrated peach juice, raspberry puree, strawberry puree, apple pulp, raspberry pulp, concentrated grape juice, concentrated aronia juice, concentrated elderberry juice.
  • a beverage comprises at least 30% by weight of the beverage of said fruit component, more preferred at least 40% by weight of the beverage of said fruit component.
  • Such foods or food compositions may be prepared in a manner known per se, e.g. by adding a carbohydrate and optionally a bacterium to a suitable food or food base, in a suitable amount.
  • a carbohydrate and optionally bacterium comprising composition intended for oral administration
  • at least part or all of a carbohydrate may be formulated in a capsule, an enteric formulation and/or a slow-release formulation
  • Such capsule and/or formulation are well known to the skilled person (21, 22, 23, 24). This is a preferred embodiment, since it will protect at least part or all of a carbohydrate from degradation in the intestinal tract before reaching the intestine wherein it will be converted into a C5 and/or a C6 SCFA.
  • a digestible carbohydrate is present as carbohydrate, it is preferred that it is formulated in such a capsule, enteric formulation and/or slow release formulation.
  • 24 well filters add 1 ml of cell suspension medium from above to 16 ml DMEM medium. Add 0.5 ml cell suspension to the apical side of the transwell filter in a 24-wells plate; add 1 ml to a 12 wells filter; add 2 ml to a 6 wells filter. Add 1, 2, 3 ml medium to the basal compartment of a 24, 12, 6 wells filter respectively. Incubate plates at 37 0 C, 5% CO 2 , change medium the next day. Change then the medium each two days. The transepithelial resistance should reach 800 ⁇ .cm 2 after 2 weeks of culture. Density is approximately 2.6*10 5 cells

Abstract

La présente invention concerne un glucide fermenté en au moins 4 heures par un sujet et destiné à être utilisé comme médicament pour la prévention, le retardement et/ou le traitement d'un trouble du tractus gastro-intestinal. De préférence, ladite fermentation induit un accroissement détectable de la production d'un acide gras à chaîne courte C5 et/ou C6 par une bactérie dans la lumière du tractus gastro-intestinal du sujet traité. Ledit accroissement est avantageusement détectable au moins 10 heures après l'administration du glucide.
PCT/NL2010/050187 2009-04-08 2010-04-08 Glucides permettant l'amélioration de la production d'un acide gras à chaîne courte c5 et/ou c6 WO2010117274A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157619 2009-04-08
EP09157619.9 2009-04-08

Publications (1)

Publication Number Publication Date
WO2010117274A1 true WO2010117274A1 (fr) 2010-10-14

Family

ID=40941849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2010/050187 WO2010117274A1 (fr) 2009-04-08 2010-04-08 Glucides permettant l'amélioration de la production d'un acide gras à chaîne courte c5 et/ou c6

Country Status (1)

Country Link
WO (1) WO2010117274A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126015A1 (fr) * 2012-02-23 2013-08-29 N. V. Nutricia Composition comprenant des oligosaccharides non digestibles
EP3075848A1 (fr) * 2015-04-01 2016-10-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Production microbiologique d'acides gras courts et leurs utilisations
WO2020043797A1 (fr) 2018-08-29 2020-03-05 Dsm Ip Assets B.V. Formulations pour améliorer la santé intestinale

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673360A1 (fr) * 1991-03-01 1992-09-04 Ard Sa Composition a base de fibres alimentaires, aliment en contenant et procede de preparation.
EP0648495A2 (fr) * 1993-07-16 1995-04-19 Hercules Incorporated Polysaccharides complexées pour des cations
WO2004052121A1 (fr) * 2002-12-12 2004-06-24 Novartis Ag Compositions prebiotiques
WO2006013588A1 (fr) * 2004-08-05 2006-02-09 Anidral S.R.L. Acide folique produisant des souches bactériennes de bifidobacterium, des formulations et leur utilisation
WO2006069422A1 (fr) * 2004-12-30 2006-07-06 Commonwealth Scientific And Industrial Research Organisation Procede et moyen benefiques pour l'intestin
US20070116837A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With Dietary Fiber and Compositions Sweetened Therewith

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673360A1 (fr) * 1991-03-01 1992-09-04 Ard Sa Composition a base de fibres alimentaires, aliment en contenant et procede de preparation.
EP0648495A2 (fr) * 1993-07-16 1995-04-19 Hercules Incorporated Polysaccharides complexées pour des cations
WO2004052121A1 (fr) * 2002-12-12 2004-06-24 Novartis Ag Compositions prebiotiques
WO2006013588A1 (fr) * 2004-08-05 2006-02-09 Anidral S.R.L. Acide folique produisant des souches bactériennes de bifidobacterium, des formulations et leur utilisation
WO2006069422A1 (fr) * 2004-12-30 2006-07-06 Commonwealth Scientific And Industrial Research Organisation Procede et moyen benefiques pour l'intestin
US20070116837A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With Dietary Fiber and Compositions Sweetened Therewith

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
BLACHE, D. ET AL.: "Oxidant stress: the role of nutrients in cell-lipoprotein interactions", PROC NUTR SOC, vol. 58, no. 3, 1999, pages 559 - 63
BORDIN, M. ET AL.: "Histone deacetylase inhibitors up-regulate the expression of tight junction proteins", MOL CANCER RES, vol. 2, no. 12, 2004, pages 692 - 701
BOREN, J. ET AL.: "The stable isotope-based dynamic metabolic profile of butyrate- induced HT29 cell differentiation", J BIOL CHEM, vol. 278, no. 31, 2003, pages 28395 - 402
CLEAR NJ; MILTON A; HUMPHREY M; HENRY BT; WULFF M; NICHOLS DJ ET AL.: "Evaluation of the Intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon", EUR J PHARM SCI., vol. 13, no. 4, 2001, pages 375 - 84
COLE ET; SCOTT RA; CONNOR AL; WILDING IR; PETEREIT HU; SCHMINKE C ET AL.: "Enteric coated HPMC capsules designed to achieve intestinal targeting", INT J PHARM., vol. 231, no. 1, 2002, pages 83 - 95
CUMMINGS, J.H. ET AL.: "PASSCLAIM--gut health and immunity", EUR J NUTR, vol. 43, no. 2, 2004, pages 11118 - 11173
FULLER, R.; G. PERDIGON; GUT FLORA: "Nutrition, Immunity and Health", 2003, PLACKWELL PUBLISHING
GAUDIER, E. ET AL.: "Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 287, no. 6, 2004, pages G1168 - G1174
GIBSON GLENN R ET AL: "Dietary modulation of the human colonic microbiota: updating the concept of prebiotics", NUTRITION RESEARCH REVIEWS,, vol. 17, no. 2, 1 December 2004 (2004-12-01), pages 259 - 275, XP009117209 *
GIBSON GR; CUMMINGS JH; MACFARLANE GT: "Use of a threestage continuous culture system to study the effect of mucin on dissimilatory sulphate reduction and methanogenesis by mixed populations of human gut bacteria", APPL ENVIRON MICROBIOL, vol. 54, 1998, pages 2750 - 5
GIBSON, G.R.; M.B. ROBERFROID: "Dietary modulation of the human colonic microbiota: introducing the concept ofprebiotics", J NUTR, vol. 125, no. 6, 1995, pages 1401 - 12
HEAD R., LE LEU R., HIGGINS J., TOPPING D., DANGAR L.: "Resistant Starch: The breakthrough fibre; latest science on energy management and digestive health", June 2005 (2005-06-01), XP002587574, Retrieved from the Internet <URL:http://www.hi-maize.com/doc/recipe/healthprof/proceedingsfinal2.pdf> *
HINNEBUSCH B.F.; MENG S.; WU J.T.; ARCHER S.Y.; HODIN R.A., J. NUTRITION, vol. 132, 2002, pages 1012 - 1017
HUYGHEBAERT N; VERMEIRE A; REMON JP: "Alternative methodfor enteric coating of HPMC capsules resulting in ready-to-use enteric-coated capsules", EUR J PHARM SCI., vol. 21, no. 5, 2004, pages 617 - 23
JACOBASCH GISELA ET AL: "Dietary resistant starch and chronic inflammatory bowel diseases", INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol. 14, no. 4-5, November 1999 (1999-11-01), pages 201 - 211, XP009011371, ISSN: 0179-1958 *
JACOBASCH, G. ET AL.: "Dietary resistant starch and chronic inflammatory bowel diseases", INT J COLORECTAL DIS, vol. 14, no. 4-5, 1998, pages 201 - 11
JOUANY JP: "Volatile fatty acids and alcohols determination in digestive contents, silage juice, bacterial culture and anaerobic fermentor contents", SCI ALIMENTS, vol. 2, 1982, pages 131 - 44
KANAUCHI, 0. ET AL.: "Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis", J GASTROENTEROL HEPATOL, vol. 16, no. 2, 2001, pages 160 - 8
KOSARAJU SL: "Colon targeted delivery systems: review of polysaccharides for encapsulation and delivery", CRIT REV FOOD SCI NUTR., vol. 45, no. 4, 2005, pages 251 - 8
KVIETYS, P.R.; D.N. GRANGER: "Effect of volatile fatty acids on blood flow and oxygen uptake by the dog colon", GASTROENTEROLOGY, vol. 80, 1981, pages 962 - 9
MANNING, T.S.; G.R. GIBSON: "Microbial-gut interactions in health and disease. Prebiotics", BEST PRACT RES CLIN GASTROENTEROL, vol. 18, no. 2, 2004, pages 287 - 98
MARIADASON JM; BARKLA DH; GIBSON PR: "Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model", AM J PHYSIOL, vol. 272, 1998, pages G705 - G712
MILLER S.J.; ZALOGA G.P.; HOGGATT A.M.; LABARRERE C; FAULK W.P., NUTRITION, vol. 21, 2005, pages 740 - 748
MINEKUS M; SMEETS-PEETERS M; BERNALIER A; MAROL-BONNIN S; HAVENAAR R; MARTEAU P; ALRIC M; FONTY G; HUIS IN'T VELD JH: "A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products", APPL MICROBIOL BIOTECHNOL, vol. 53, 1998, pages 108 - 14
OGAWA, H. ET AL.: "Butyrate modulates gene and protein expression in human intestinal endothelial cells", BIOCHEM BIOPHYS RES COMMUN, vol. 309, no. 3, 2003, pages 512 - 9
PENG L; HE Z; CHEN W; HOLZMAN IR; LIN J: "Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer of intestinal barrier", PEDIATRIC RESEARCH, vol. 61, 2007, pages 37 - 41
ROSIGNOLI, P. ET AL.: "Protective activity of butyrate on hydrogen peroxide- induced DNA damage in isolated human colonocytes and HT29 tumour cells", CARCINOGENESIS, vol. 22, no. 10, 2001, pages 1675 - 80
TARRERIAS, A.L. ET AL.: "Short-chain fatty acid enemas fail to decrease colonic hypersensitivity and inflammation in TNBS-induced colonic inflammation in rats", PAIN, vol. 100, no. 1-2, 2002, pages 91 - 7
TSUKAHARA, T. ET AL.: "Stimulation of butyrate production in the large intestine of weaning piglets by dietaryfructooligosaccharides and its influence on the histological variables of the large intestinal mucosa", J NUTR SCI VITAMINOL (TOKYO), vol. 49, no. 6, 2003, pages 414 - 21
VAN NUENEN HMC; MEYER PD; VENEMA K: "The effect of various inulins and Clostridium difficile on the metabolic activity of the human colonic microbiota in vitro", MICROB ECOL HEALTH DIS, vol. 15, 2003, pages 137 - 44
VENEMA K ET AL., MICROBIAL ECOLOGY IN HEALTH AND DISEASE, vol. 17, 2005, pages 47 - 5719
VENEMA K; NUENEN HMC; SMEETS-PEETERS M; MINEKUS M; HAVENAAR R: "TNO's in vitro large intestinal model: an excellent screening tool for functional food and pharmaceutical research", EMAHRUNG/NUTRITION, vol. 24, 2000, pages 558 - 64
VENKATRAMAN, A. ET AL.: "Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 285, no. 1, 2003, pages G177 - 84
WILLEMSEN, L.E. ET AL.: "Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts", GUT, vol. 52, no. 10, 2003, pages 1442 - 7

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126015A1 (fr) * 2012-02-23 2013-08-29 N. V. Nutricia Composition comprenant des oligosaccharides non digestibles
EP3075848A1 (fr) * 2015-04-01 2016-10-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Production microbiologique d'acides gras courts et leurs utilisations
WO2016156548A1 (fr) * 2015-04-01 2016-10-06 Johann Wolfgang Goethe-Universität Frankfurt am Main Production microbiologique d'acides gras à chaine courte et utilisations associées
US11078468B2 (en) 2015-04-01 2021-08-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Microbiological production of short fatty acids and uses thereof
WO2020043797A1 (fr) 2018-08-29 2020-03-05 Dsm Ip Assets B.V. Formulations pour améliorer la santé intestinale

Similar Documents

Publication Publication Date Title
Mohanty et al. Prebiotics and synbiotics: Recent concepts in nutrition
Shah et al. Effects of prebiotic dietary fibers and probiotics on human health: With special focus on recent advancement in their encapsulated formulations
Tawfick et al. Inulin fructans in diet: Role in gut homeostasis, immunity, health outcomes and potential therapeutics
Rosa et al. Dairy products with prebiotics: An overview of the health benefits, technological and sensory properties
NL2004201C2 (en) Use of sialyl oligosaccharides to modulate the immune system.
EP2117355B1 (fr) Procédé permettant d&#39;améliorer des aptitudes avec une composition comprenant un saccharide non digestible
Younis et al. Health benefits and application of prebiotics in foods.
EP2323669B1 (fr) Arabinoxylane pour moduler la fonction barrière de la surface intestinale
WO2009154463A2 (fr) Le butyrate comme médicament permettant d&#39;améliorer la perception viscérale chez l&#39;homme
AU2003262600B2 (en) Novel use of carbohydrates and compositions
TW201233334A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
JP6479768B2 (ja) 新規ラクトバチラス・パラカゼイ株
KR20150018784A (ko) 샤도네이씨 생성물의 치료용도
JP2020512837A (ja) 消化器の健康、体重管理、免疫の強化および健康の改善のためのマルチ繊維プレバイオティクス組成物
EP2710901A1 (fr) Composition de supplément diététique
Althubiani et al. Plant-derived prebiotics and its health benefits
AU2011314299B2 (en) Compositions and methods for augmenting kidney function
Glibowski et al. Prebiotic and synbiotic foods
Demirci et al. Prebiyotik oligosakkaritlerin kaynakları, üretimleri ve gıda uygulamaları
WO2010117274A1 (fr) Glucides permettant l&#39;amélioration de la production d&#39;un acide gras à chaîne courte c5 et/ou c6
EP4249052A1 (fr) Composition pour amélioration de la flore bactérienne intestinale, et composition pour inhibition de la production de matière putréfiée intestinale
WO2024043298A1 (fr) Composition pour améliorer la flore bactérienne intestinale
KR20230116027A (ko) F. 프라우스니치이 존재도를 촉진하는 데 사용하기위한 2&#39;-푸코실락토스
KR20220155007A (ko) 아세틸아디핀산이전분을 포함하는 장내 균총 개선용 조성물
Malinowska-Pańczyk Probiotics and Prebiotics in Food

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10711949

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10711949

Country of ref document: EP

Kind code of ref document: A1